BOSTON, Nov. 10, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence
Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursday, November
17, 2016 at 4:40 p.m. GMT.
As previously announced, ZIOPHARM will host a conference call and webcast slide presentation Thursday, November
17, 2016, at 8:00 am ET to discuss information featured at the Society for Neuro-Oncology (SNO) Annual Meeting, including updated
data from the Company’s Phase 1 study of Ad-RTS-hIL-12 + veledimex in high-grade glioma. The call can be accessed by dialing (844)
309-0618 (U.S. and Canada) or (661) 378-9465 (international). The passcode for the conference call is 11110235. To access the
slides and live audio webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website
at www.ziopharm.com. A replay of the call will be available on the Company's website for two (2)
weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression,
control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer
and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and
the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use
non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together
with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene
expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both
clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 locchiogrosso@ziopharm.com David Pitts Argot Partners 212-600-1902 david@argotpartners.com
